281 related articles for article (PubMed ID: 32405630)
1. Chronic Use of Long-Acting Somatostatin Analogues (SSAs) and Exocrine Pancreatic Insufficiency (EPI) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Under-recognized Adverse Effect.
Saif MW; Romano A; Smith MH; Patel R; Relias V
Cancer Med J; 2020; 3(2):75-84. PubMed ID: 32405630
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study.
Lamarca A; McCallum L; Nuttall C; Barriuso J; Backen A; Frizziero M; Leon R; Mansoor W; McNamara MG; Hubner RA; Valle JW
Expert Rev Gastroenterol Hepatol; 2018 Jul; 12(7):723-731. PubMed ID: 29923433
[TBL] [Abstract][Full Text] [Related]
3. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
[TBL] [Abstract][Full Text] [Related]
4. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.
Whitcomb DC; Buchner AM; Forsmark CE
Gastroenterology; 2023 Nov; 165(5):1292-1301. PubMed ID: 37737818
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
6. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
7. Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Saif MW; Fu J; Smith MH; Weinstein B; Relias V; Daly KP
J Pancreat Cancer; 2018; 4(1):64-71. PubMed ID: 30788459
[No Abstract] [Full Text] [Related]
8. Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET).
Ström T; Kozlovacki G; Myrenfors P; Almquist M
Patient Prefer Adherence; 2019; 13():1799-1807. PubMed ID: 31695341
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs.
Rinzivillo M; De Felice I; Magi L; Annibale B; Panzuto F
Pancreatology; 2020 Jul; 20(5):875-879. PubMed ID: 32684368
[TBL] [Abstract][Full Text] [Related]
10. Exocrine pancreatic insufficiency after bariatric surgery: a bariatric surgery center of excellence experience.
Moore HN; Chirco AR; Plescia T; Ahmed S; Jachniewicz B; Rajasekar G; Ali MR; Lyo V
Surg Endosc; 2023 Feb; 37(2):1466-1475. PubMed ID: 35768735
[TBL] [Abstract][Full Text] [Related]
11. [Antiproliferative Effect of Somatostatin Analogs - Data Analyses and Clinical Applications in the Context of the CLARINET Study].
Bencsiková B
Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
[TBL] [Abstract][Full Text] [Related]
12. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
[TBL] [Abstract][Full Text] [Related]
13. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Apr; 39(4):1754-1771. PubMed ID: 35190997
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future.
Öberg K; Lamberts SW
Endocr Relat Cancer; 2016 Dec; 23(12):R551-R566. PubMed ID: 27697899
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.
Massironi S; Conte D; Rossi RE
Scand J Gastroenterol; 2016; 51(5):513-23. PubMed ID: 26605828
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
[TBL] [Abstract][Full Text] [Related]
18. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
19. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
20. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
